Investment Thesis — Masimo Corporation
Masimo is misunderstood as a slow-growth medtech player, but its recent consumer health pivot and underappreciated IP portfolio position it for a rerating. The market is underestimating the monetization potential of its non-invasive monitoring technology beyond hospitals. Near-term volatility masks a multi-year opportunity for outsized returns as new revenue streams materialize.
Catalysts
- Resolution of Apple patent litigation with favorable settlement
- Successful launch and adoption of consumer health products
- New licensing agreements for non-invasive monitoring technology
Risk Factors
- Failure to penetrate consumer health market
- Unfavorable legal outcomes in ongoing IP litigation
- Integration issues with acquired businesses impacting margins
Key Debates
Masimo reverses -0.40% Fwd Rev Growth to 3% by Q4 2024
Spinoff of Sound United segment unlocks 15% shareholder value by Q3 2024
Apple Watch patent dispute resolution impacts MASI's IP value by Q4 2024